Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HEC96719 in Healthy Chinese Volunteers
NCT04194242Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing HEC96719 with Placebo (2 arms). Primary endpoint: Adverse events of the single ascending-dose. Started Jan 2020; status: completed.
02
Drugs
hec96719
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04194242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194242.